Is There a Need to Further Subclassify pt2 Renal Cell Cancers as Implemented by the Revised 7th TNM Version?
|
|
- Anthony King
- 6 years ago
- Views:
Transcription
1 EUROPEAN UROLOGY 59 (2011) available at journal homepage: Kidney Cancer Is There a Need to Further Subclassify pt2 Renal Cell Cancers as Implemented by the Revised 7th TNM Version? Sandra Waalkes a,1, Frank Becker b,1, Andres J. Schrader c,d,1, Martin Janssen b, Gerd Wegener e, Axel S. Merseburger a, Mark Schrader c, Rainer Hofmann d, Michael Stöckle b, Markus A. Kuczyk a, * a Department of Urology and Urologic Oncology, Hannover University Medical School, Hannover, Germany b Department of Urology, University Clinics of Saarland, Homburg/Saar, Germany c Department of Urology, Ulm University Medical School, Ulm, Germany d Department of Urology, Philipps University, Marburg, Germany e Clinical Cancer Registry, Hannover University Medical School, Hannover, Germany Article info Article history: Accepted October 5, 2010 Published online ahead of print on October 15, 2010 Keywords: Renal cell cancer Prognosis Survival TNM 2010 Abstract Background: The recently modified TNM classification of renal cell carcinoma (RCC) (7th edition) has implemented a subdivision of pt2 tumours into stage pt2a (>7 or 10 cm) versus pt2b disease (>10 cm). Objective: Our aim was to evaluate whether this subdivision of pt2 RCC is justified due to a clinical prognosis divergence between the two groups (pt2a vs pt2b) Design, setting, and participants: In total, 5122 patients were subjected to either radical nephrectomy or nephron-sparing surgery at three centres in Germany (University Hospitals of Hannover, Homburg/Saar, and Marburg). Patients were reclassified into stage pt2a and pt2b according to the maximum tumour diameter as suggested by the 7th revised version of the TNM classification system. Measurements: The t test and Fisher exact test were applied to evaluate the comparability of the two groups (pt2a vs pt2b) regarding several additional patients and tumourspecific characteristics of known prognostic relevance for RCC. Univariable (Kaplan-Meier analysis) and multivariable statistical analyses (Cox proportional hazards regression model) were applied to identify a possible difference between the two groups (pt2a vs pt2b) regarding cancer-specific survival (CSS). Results and limitations: Applying the new TNM classification, 579 previously pt2-staged patients were divided into 445 (76.9%) with pt2a and 134 (23.1%) with pt2b tumours. Kaplan-Meier curves revealed no significant difference in CSS between pt2a and pt2b patients; 5-yr CSS was 79.0% and 74.1%, respectively (p = 0.38). When applying multivariable analysis, unlike tumour grade and N/M status, pt2 subclassification failed to independently predict survival in RCC patients. Conclusions: The new subclassification of pt2 RCC into two different subgroups as suggested by the latest modification of the TNM system does not yield additional/ prognostic information. # 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved. 1 These authors contributed equally to this publication. * Corresponding author. Department of Urology, Hannover Medical School, Carl-Neuberg-Str. 1, D Hannover, Germany. Tel ; Fax: address: kuczyk.markus@mh-hannover.de (M.A. Kuczyk) /$ see back matter # 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved. doi: /j.eururo
2 EUROPEAN UROLOGY 59 (2011) Introduction The Union Internationale Contre le Cancer and the American Joint Committee on Cancer (AJCC) proposed the first TNM staging system for renal cell carcinoma (RCC) in 1978 [1]. The TNM criteria define the anatomic extent of disease and stage. They have been shown to correlate with prognosis and to provide important information for optimal patient management. On the basis of new evidence, the TNM system was subsequently modified to improve its prognostic accuracy in 1987, 1997, 2002, and, most recently, in 2010 [1 4]. Because primary tumour size is a key component of the TNM staging system, it remains one of the most important prognostic factors for RCC [5]. The prognostic significance of tumour diameter for localised disease has therefore been investigated in a number of previous studies [6 10]. As a consequence, many modifications of the TNM staging system were primarily made to take different tumour size cut-off points into account. The current 7th TNM edition was in part established on data from a study by Frank et al, who evaluated the optimal cut-off point to stratify localised RCC [6]. This led to an additional substratification of T2 tumours into T2a (>7 but 10 cm) and T2b (>10 cm). The aim of this large retrospective multicentre study was to evaluate the new TNM staging system with respect to delineation of stage T2a versus T2b tumours on patients clinical outcome following surgery. 2. Patients and methods 2.1. Patient selection and pathologic features A total of 5122 RCC patients treated from 1975 to 2009 by radical nephrectomy or nephron-sparing surgery at three university hospitals in Germany (Departments of Urology in Hannover, Homburg/Saar, and Marburg) were included. Information on patients and tumour characteristics, such as age, sex, tumour diameter, stage, presence of regional lymph node or distant metastases, histologic subtype, and Fuhrman grade, was obtained from institutional databases. Tumours were reclassified according to the current TNM version by recognising their largest diameter (in centimetres) as indicated in the pathologic reports (pt2a: tumour diameter >7 cm but 10 cm; pt2b: >10 cm) Follow-up The duration of the follow-up was calculated from date of surgery to the date of death or last follow-up. Death was assessed as either cancer related or unrelated. The primary end point of this study was cancerspecific survival (CSS). Information about the exact date as well as cause of death for each patient was received from the patient s general practitioner, a close family member, or the patient s hospital records if she or he had been followed up or died in one of our institutions. Followup assessment ended in November Until then, all patients data were updated regularly at least every 6 mo Statistical methods Continuous variables were reported as mean value and standard deviation (SD) or median value and interquartile ranges (IQRs) in the case of parametric or nonparametric distribution, respectively. Normal distribution of continuous parameters such as age, tumour size, and follow-up period were tested using the Kolmogorov-Smirnov test. Fisher exact tests were conducted to assess the differences in covariate distributions between pt2 categories. Age and tumour size were correlated applying the Spearman test. Kaplan-Meier estimates of survival time were calculated, and subgroups were compared with the log-rank test statistic. Multivariable Cox regression models were used to assess the association between survival and pt2 subgroups adjusted for different clinical and patient covariates (i.e., age, sex, tumour grade, histologic subtype, metastatic status). SPSS 17.0 (SPSS Inc, Chicago, IL, USA) was used for statistical assessment. In all tests, a two-sided p value <0.05 was considered to indicate significance. 3. Results 3.1. Patient and tumour characteristics In total, 579 of 5122 patients (11.3%) were classified as harbouring RCCs of stage pt2 (76.3% clear cell, 9.7% papillary, and 3.5% chromophobe subtypes; 10.5% unclassified or other RCC subtype). Following reclassification according to the 7th TNM edition, 445 patients (76.9%) and 134 patients (23.1%) were classified as pt2a or pt2b, respectively (Table 1). The mean age for the total cohort was 59.3 yr (12.7). In total, 353 (61%) were male and 226 (39%) were female. The mean tumour size of all patients was 9.5 cm (2.9 cm): 8.2 cm and 13.6 cm in the subgroups of patients with pt2a and pt2b tumours, respectively. Patients revealing tumours classified as pt2b were significantly younger than those with pt2a disease (mean: 57 vs 60 yr; p = 0.015; t test); age correlated negatively with tumour size (r = 0.09; p = 0.025; Spearman). Using univariable analyses, the two groups were comparable in terms of the remaining patients and tumour characteristics of potential prognostic relevance: Neither sex nor histologic subtype, nodal status/distant metastasis, or tumour grade correlated with the newly defined pt2 subgroups (Table 1) Survival analysis The median follow-up for the entire cohort was 49 mo (IQR:18 102mo):56mo(IQR:21 109mo)and40mo (IQR: mo) for pt2a and pt2b tumours, respectively (p = 0.003; Mann-Whitney test). The median follow-up for all patients alive and free of recurrence (n =302)was64 mo (IQR: mo): 73 mo (IQR: mo) and 43 mo (IQR: mo) for pt2a and pt2b tumours, respectively (p =0.001). At the time of the last follow-up evaluation, 124 patients (23.4%) had died due to tumour progression: 95 patients (21.3%) and 29 patients (21.6%) with pt2a or pt2b disease, respectively. In addition, 2.9% and 5.2%, respectively, of all patients experienced recurrence but were still alive (p = 0.75; Fisher exact test). Applying Kaplan-Meier analysis to compare the two pt2 subgroups, no significant difference in CSS could be demonstrated (p = 0.38; log-rank test). The calculated 5-yr CSS for patients with pt2a and pt2b RCC was 79.0% and 74.1%, respectively (Fig. 1a).
3 260 EUROPEAN UROLOGY 59 (2011) Table 1 Patient and tumour characteristics * Variable pt2a pt2b RR 95% CI p value Test Total (%) 445 (76.9) 134 (23.1) Age, yr, mean ( SD) 60.0 (12.1) 56.7 (14.5) t test Sex, No. (%) 0.76 Fisher exact Male 273 (61.3) 80 (59.7) 1 Reference Female 172 (38.7) 54 (40.3) Histology, No. (%) Fisher exact Clear cell 347 (78.2) 94 (70.1) 1 Reference Non clear cell 97 (21.8) 40 (29.9) LN metastases, No. (%) y 0.83 Fisher exact N 421 (94.6) 126 (94.0) 1 Reference N+ 24 (5.4) 8 (6.0) Pulmonary/visceral metastasis, No. (%) y 0.75 Fisher exact M 396 (89.0) 121 (90.3) 1 Reference M+ 49 (11.0) 13 (9.7) Metastasis (N and/or M+), No. (%) y 0.78 Fisher exact N, M 379 (85.2) 116 (86.6) 1 Reference N+ and/or M+ 66 (14.8) 18 (13.4) Grade, No. (%) 0.59 Fisher exact G1 61 (13.7) 23 (17.2) 1 Reference G2 270 (60.7) 74 (55.2) G3 92 (20.7) 29 (21.6) G4 21 (4.7) 8 (6.0) CI = confidence interval; M = distant visceral/pulmonal disease; N = nodal disease; RR = relative risk; SD = standard deviation. * Comparability of both groups (pt2a vs pt2b) according to all variables evaluated except for patients age (patients with tumours classified as pt2b were significantly younger compared with those diagnosed with pt2a disease). y At time of renal surgery. Because the presence of metastasis at diagnosis and/or at the time of surgery is surely the most important confounder concerning overall survival (Table 2), we subsequently compared the CSS of the two pt2 subcategories excluding those patients with nodal and/or distant metastasis. Interestingly, adjusting for metastasis at the time of surgery, we still could not show significant differences in CSS Table 2 Multivariable analysis of patients and tumour characteristics with regard to their prognostic impact on cancerspecific long-term survival (Cox regression analysis) Variable HR 95% CI p value Age, yr * Sex 0.06 Female 1 Reference Male Grade 0.06 G1 1 Reference G G G Metastasis y <0.001 N0/M0 1 Reference N+ and/or M Histology z 0.2 n-ccrcc 1 Reference ccrcc pt2 subdivision 0.49 pt2a 1 Reference pt2b CI = confidence interval; HR = hazard ratio. * Continuous variable. y At time of renal surgery: N1M0, N1M1, N0M1. z Clear cell renal cell carcinoma (ccrcc) versus other histologic classifications (n-ccrcc). between pt2 subcategories (5-yr CSS: 85.2% and 80.1%, respectively; p = 0.1, log-rank test; Fig. 1b). Applying univariable analysis, in contrast to sex (p = 0.06), T2 subcategories (p = 0.38), and histologic subtype (p = 0.46), age (p = 0.02, favouring younger patients), nodal (p < 0.001) or visceral involvement (p < 0.001), and tumour grade (p = 0.001; Cox regression) correlated with CSS. In contrast, employing multivariable analysis including these potential prognostic factors for patients with kidney cancer, only age (favouring younger patients; p = 0.02, Cox regression analysis) and metastatic disease (N+ and/or M+; p < 0.001) could be confirmed as significant independent prognostic markers for pt2 RCC patients (Table 2). The classification of patients into pt2 subgroups (T2a vs T2b) as recommended by the latest TNM edition again did not qualify as a variable of independent prognostic importance (p = 0.49; Cox regression). Using multivariable analysis and focussing on the subgroup of patients with localised disease (pt2, N0, M0), unlike age (p = 0.001), pt2 subclassification (p = 0.10) again could not be identified as an independent prognostic marker for tumour-specific survival. However, applying multivariable analysis including all patients and exchanging pt2 subclassification with tumour size as a continuous variable, in addition to age (p = 0.01), the tumour diameter was identified as an independent prognostic parameter (p = 0.01). 4. Discussion Tumour size is a key component of the TNM staging system and remains one of the most important prognostic factors for RCC. Through the years the TNM system has been
4 [()TD$FIG] EUROPEAN UROLOGY 59 (2011) Fig. 1 Clinical outcome did not correlate with pt2 subcategories (Kaplan-Meier method). (a) The 5-yr cancer-specific survival (CSS) rate for the whole cohort of pt2 patients was 78.0% and did not differ significantly between pt2a and pt2b tumours (79.0% vs 74.1%; p = 0.38; log-rank test). (b) For the subgroup of patients without regional lymph node or distant metastases (N0/M0), the 5-yr CSS rates were 85.2% and 80.1% for stage pt2a and pt2b, respectively (p = 0.10; log-rank test). revised repeatedly. In the 1987 edition of the TNM classification [3], the cut-off point separating T1 from T2 was set at 2.5 cm. This change was based on the assumption that smaller tumours have a very low risk of metastases. However, this categorisation was found to be limited because only a few tumours were <2.5 cm [7]. Several additional studies showed prognostic significance for various other cut-off points [8 11], irrespective of the TNM classification. Ficarra et al proposed a tumour size break point of 5.5 cm for patients with organ-confined disease [12]. In 2007, Klatte et al [13] evaluated a group of 706 patients with pt2 RCC and identified 11 cm as the ideal tumour size cut-off. Patients with a tumour size of 11 cm had a significantly longer CSS compared with patients with tumours >11 cm. However, according to Karakiewicz et al and Moch et al, tumour size could be shown to be
5 262 EUROPEAN UROLOGY 59 (2011) significantly associated with outcome when modelled continuously, irrespective of specific cut-off points [14,15]. The probability of death increased 3.5 times for each doubling of tumour size [16]. In the 7th edition of the AJCC Cancer Staging Manual, the results of a total of patients (for ) from the National Cancer Data Base (NCDB; org/cancer/ncdb/index.html) regarding the impact of size on CSS of T2 patients are presented. The 5-yr CSS for organconfined tumours >7 cm but 10 cm was 57% compared with 47.5% for tumours with a diameter >10 cm. With a median 5-yr-survival rate of 79.0% for T2a patients versus 74.1% for T2b, we were not able to confirm a significant difference in survival for patients with <10 cm or >10 cm T2 RCC. Furthermore, patients with pt2 RCC in our study population seemed to live significantly longer than the patients included in the NCDB database. The rationale for changes in the TNM system is usually based on new evidence from large multicentre clinical studies. In contrast, the current T2 subclassification was based on a study published by Frank et al [6] in 2005 analysing 544 patients from the Mayo Clinic. Their data indicated that patients with tumours >7 cm and <10 cm had a worse outcome than those with pt1b RCC. Furthermore, patients with tumours 10 cm had a worse prognosis than those with 7- to 10-cm tumours but a better outcome than those with pt3a RCC. Only recently, including patients from 16 different centres, Novara et al [5] were able to validate the 7th edition of the TNM staging system for RCC as published in this journal. They concluded that the latest changes of the primary tumour staging system for kidney cancer are a powerful predictor of CSS. Regarding the subclassification of pt2 tumours, they observed a significant difference in 5-yr CSS of 85.4% and 70% for patients with pt2a and pt2b RCC, respectively. In contrast to these two studies with a similar size and a slightly shorter follow-up time, we were not able to confirm a significant difference between pt2a and pt2b tumours. We cannot explain why our results differ from the previously published studies by Novara et al and Frank et al [5,6]. However, there are several differences in patients and tumour characteristics that might account for the different outcome. In our trial the mean tumour size for all pt2 tumours was 9.4 cm compared with 10.4 cm in the study published by Frank et al [6]. Mean tumour sizes of the pt2 subgroups investigated by Frank et al and Novara et al have not been specified in their publications. It could be conceivable that the meantumourdiameterof pt2a tumours might have been bigger and that of pt2b tumours smaller in our trial. Comparing the number of patients in each pt2 subgroup in the study by Frank et al [6], the pt2 subgroups, surprisingly, were almost equal in size (49.4% pt2a and 50.6% pt2b). In contrast, in the study by Novara et al [5] (74.1% pt2a and 24.9% pt2b) and in our analysis (76.9% pt2a and 23.1% pt2b), the distribution between the pt2 subgroups was very similar, with almost three times more patients in thept2agroup.afurther point is that the follow-up periods differed between the two pt2 subgroups. We cannot completely rule out that this fact might have influenced our results. However, neither Novara et al nor Frank et al [5,6] indicated the follow-up period for their pt2 subgroups. Hence a potential influence of the length of follow-up periods in Frank s and Novara s studies as an explanation for different outcomes of those trials and our own cannot be ruled out either. Our study had several important limitations. First and foremost are the limitations inherent in retrospective analysis, the lack of central pathologic review, and a relatively small number of pt2 patients. Thus we cannot completely rule out that our study was underpowered to observe different outcomes between patients with pt2a and pt2b disease. This is supported by the fact that tumour diameter as a continuous variable is significantly associated with CSS in multivariable analysis, in contrast to the novel T2 subcategories. A further limitation was that patients revealing tumours classified as pt2b were significantly younger than those with pt2a disease. Because age was included in the multivariable analysis, it is unlikely that this fact might have influenced our results concerning the significance of T2 subdivision. 5. Conclusions The current study evaluates the prognostic importance of the new subdivision of pt2 RCC. It was not possible to confirm a substantially different outcome for the substratification of T2 into T2a and T2b in this large patient collective. Although our data were generated by the evaluation of a database that should be representative because of its size, additional investigations should be awaited before the new subdivision of pt2 RCC is abandoned. Author contributions: Markus A. Kuczyk had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Kuczyk, Waalkes, Schrader. Acquisition of data: Waalkes, Schrader, Becker, Janssen, Wegener, Stöckle, Hofmann. Analysis and interpretation of data: Schrader, Waalkes. Drafting of the manuscript: Waalkes, Schrader, Becker, Kuczyk. Critical revision of the manuscript for important intellectual content: Kuczyk, Schrader, Merseburger. Statistical analysis: Schrader. Obtaining funding: None. Administrative, technical, or material support: Wegener. Supervision: Kuczyk. Other (specify): None. Financial disclosures: I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/ affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None. Funding/Support and role of the sponsor: None. Acknowledgement statement: We thank Dr. Jens Dreyhaupt, Institute for Medical Biometrie, Ulm University, for supervising our statistical computations.
6 EUROPEAN UROLOGY 59 (2011) References [1] Hermanek P, Henson DE, Hutter RVP, Sobin LH, editors. TNM supplement. A commentary on uniform use. Berlin, Germany: Springer; [2] Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, editors. AJCC cancer staging manual. ed 6. New York, NY: Springer; [3] Sobin LH, Hermanek P, editors. TNM classification of malignant tumours. ed 4. Berlin, Germany: Springer; [4] Sobin LH, Wittekind C, editors. TNM classification of malignant tumours. ed 5. New York, NY: Wiley-Liss; [5] Novara G, Ficarra V, Antonelli A, et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol 2010;58: [6] Frank I, Blute ML, Leibovich BC, et al. pt2 classification for renal cell carcinoma. Can its accuracy be improved? J Urol 2005;173: [7] Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000;89: [8] Gettman MT, Blute ML, Spotts B, Bryant SC, Zincke H. Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 2001;91: [9] Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 1999;162: [10] Kinouchi T, Saiki S, Meguro N, et al. Impact of tumor size on the clinical outcomes of patients with Robson State I renal cell carcinoma. Cancer 1999;85: [11] Zisman A, Pantuck AJ, Chao D, et al. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol 2001;166:54 8. [12] Ficarra V, Guille F, Schips L, et al. Proposal for revision of the TNM classification system for renal cell carcinoma. Cancer 2005;104: [13] Klatte T, Patard JJ, Goel RH, et al. Prognostic impact of tumor size on pt2 renal cell carcinoma: an international multicenter experience. J Urol 2007;178:35 40, discussion 40. [14] Karakiewicz PI, Lewinshtein DJ, Chun FK-H, et al. Tumor size improves the accuracy of TNM predictions in patients with renal cancer. Eur Urol 2006;50: [15] Moch H, Artibani W, Delahunt B, et al. Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol 2009;56: [16] Delahunt B, Kittelson JM, McCredie MR, Reeve AE, Stewart JH, Bilous AM. Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma: assessment of TNM T1 and T2 tumor categories and comparison with other prognostic parameters. Cancer 2001;94:
Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma
ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI
More informationValidation of the 2009 TNM Classification for Renal Cell Carcinoma: Comparison with the 2002 TNM Classification by Concordance Index
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.8.524 Urological Oncology Validation of the 2009 TNM Classification for Renal Cell Carcinoma: Comparison with the 2002 TNM Classification by Concordance
More informationPrognostic Factors and Staging Systems for Renal Cell Carcinoma
european urology supplements 6 (2007) 623 629 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors and Staging Systems for Renal Cell Carcinoma Vincenzo Ficarra
More informationPrognostic factors in localized renal cell cancer
Original Article PROGNOSTIC FACTORS IN LOCALIZED RENAL CELL CANCER KNIGHT and STADLER Prognostic factors in localized renal cell cancer David A. Knight and Walter M. Stadler Section of Hematology/Oncology,
More informationKey Words. Metastatic kidney cancer Prognosis Body mass index BMI Body surface area BSA Visceral fat Subcutaneous fat Obesity Overweight
The Oncologist Genitourinary Cancer: Renal, Bladder, and Testicular Does Obesity Influence the Prognosis of Metastatic Renal Cell Carcinoma in Patients Treated with Vascular Endothelial Growth Factor Targeted
More informationUrinary Collecting System Invasion is an Independent Prognostic. Factor in Organ Confined Renal Cell Carcinomas.
Author manuscript, published in "Journal of Urology The 2009;182(3):854-9" DOI : 10.1016/j.juro.2009.05.017 Urinary Collecting System Invasion is an Independent Prognostic Factor in Organ Confined Renal
More informationeuropean urology 52 (2007)
european urology 52 (2007) 1428 1437 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Platelet Count and Preoperative Haemoglobin Do Not Significantly Increase
More informationEUROPEAN UROLOGY 60 (2011)
EUROPEAN UROLOGY 60 (2011) 458 464 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priorty Kidney Cancer Editorial by Christian G. Stief on pp. 465 466 of this issue
More informationBone Metastases in Muscle-Invasive Bladder Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
More informationNephron-Sparing Surgery versus Radical Nephrectomy in the Treatment of Intracapsular Renal Cell Carcinoma up to 7 cm
european urology 53 (2008) 803 809 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Nephron-Sparing Surgery versus Radical Nephrectomy in the Treatment of Intracapsular
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationLymphadenectomy in RCC: Yes, No, Clinical Trial?
Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University
More informationLymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity
EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:
More informationComparison of Partial and Radical Nephrectomy for pt1b Renal Cell Carcinoma
www.kjurology.org DOI:10.4111/kju.2010.51.9.596 Urological Oncology Comparison of Partial and Radical Nephrectomy for pt1b Renal Cell Carcinoma Jong Min Kim, Phil Hyun Song, Hyun Tae Kim, Tong Choon Park
More informationJMSCR Vol 06 Issue 12 Page December 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i12.76 Study of Prognostic Factors
More informationComparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population
DOI 10.1007/s10147-015-0812-9 ORIGINAL ARTICLE Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population Yasunobu
More informationLaboratory for Quantitative Medicine Technical Report #2 April 10, Equation Parameters
Laboratory for Quantitative Medicine Technical Report #2 April 10, 2009 Equation Parameters This report summarizes all the equation parameters used by the web-based calculators, and provides information
More informationEUROPEAN UROLOGY 61 (2012)
EUROPEAN UROLOGY 61 (2012) 1156 1161 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Kidney Cancer Editorial by Alvin C. Goh and Inderbir S. Gill on pp. 1162
More informationDebate: Lymphadenectomy is Important in mrcc, CON P. Mulder, M.D., Ph.D. JJ. Patard, MD, Ph.D.
Debate: Lymphadenectomy is Important in mrcc, CON P. Mulder, M.D., Ph.D. JJ. Patard, MD, Ph.D.. Eighth European International Kidney Cancer Symposium Budapest 03-04 May 2013 The role of LND In organ confined
More informationAndrogen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?
Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? New Frontiers in Urologic Oncology Juan Chipollini, MD Clinical Fellow Department of Genitourinary Oncology Moffitt Cancer
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters
Preoperative Neutrophil-to-Lymphocyte Ratio and Neutrophilia Are Independent Predictors of Recurrence in Patients with Localized Papillary Renal Cell Carcinoma The Harvard community has made this article
More informationPartial Nephrectomy Is Associated with Improved Overall Survival Compared to Radical Nephrectomy in Patients with Unanticipated Benign Renal Tumours
EUROPEAN UROLOGY 58 (2010) 293 298 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Partial Nephrectomy Is Associated with Improved Overall Survival Compared to
More informationPrognostic Relevance of the Histological Subtype of Renal Cell Carcinoma
Clinical Urology Prognostic Relevance of the Histological Subtype of RCC International Braz J Urol Vol. 34(1): 3-8, January - February, 2008 Prognostic Relevance of the Histological Subtype of Renal Cell
More informationComparison of Long-Term Results After Nephron-Sparing Surgery and Radical Nephrectomy in Treating 4- to 7-cm Renal Cell Carcinoma
:3-8 3 Comparison of Long-Term Results After Nephron-Sparing Surgery and Radical Nephrectomy in Treating 4- to 7-cm Renal Cell Carcinoma Daimantas Milonas, Giedrius Skulčius, Ruslanas Baltrimavičius, Stasys
More informationThe impact of tumour size on the probability of synchronous metastasis and survival in renal cell carcinoma patients: a population-based study
Ingimarsson et al. BMC Urology 2014, 14:72 RESEARCH ARTICLE Open Access The impact of tumour size on the probability of synchronous metastasis and survival in renal cell carcinoma patients: a population-based
More informationOverall Survival and Development of Stage IV Chronic Kidney Disease in Patients Undergoing Partial and Radical Nephrectomy for Benign Renal Tumors
EUROPEAN UROLOGY 64 (2013) 600 606 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Kidney Cancer Editorial by Alexander Kutikov, Marc C. Smaldone and Robert
More informationPROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH CHEMOTHERAPY
Journal of IMAB ISSN: 1312-773X http://www.journal-imab-bg.org http://dx.doi.org/10.5272/jimab.2016221.1045 Journal of IMAB - Annual Proceeding (Scientific Papers) 2016, vol. 22, issue 1 PROGNOSTIC FACTORS
More informationORIGINAL ARTICLE. International Journal of Surgery
International Journal of Surgery (2013) 11(S1), S90 S94 Contents lists available at ScienceDirect International Journal of Surgery journal homepage: www.journal-surgery.net ORIGINAL ARTICLE Lymph node
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationSurgical Management of Renal Cancer. David Nicol Consultant Urologist
Surgical Management of Renal Cancer David Nicol Consultant Urologist Roles of Surgery 1. Curative intervention localised disease 2. Symptomatic control advanced disease 3. Augmentation of efficacy of systemic
More informationUpper urinary tract urothelial carcinomas (UTUC)
Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract Manel Mellouli 1 *, Slim Charfi 1, Walid Smaoui 2, Rim Kallel 1, Abdelmajid Khabir 1, Mehdi Bouacida
More informationRCC in Adolescents and Young Adults (AYAs): Diagnosis and Management
RCC in Adolescents and Young Adults (AYAs): Diagnosis and Management Nicholas G. Cost, M.D. Assistant Professor, Department of Surgery, Division of Urology University of Colorado Cancer Center Fifteenth
More informationPerigastric lymph node metastases in gastric cancer: comparison of different staging systems
Gastric Cancer (1999) 2: 201 205 Original article 1999 by International and Japanese Gastric Cancer Associations Perigastric lymph node metastases in gastric cancer: comparison of different staging systems
More informationMetastatic Potential in Renal Cell Carcinomas =7 cm: Swedish Kidney Cancer Quality Register Data
EUROPEAN UROLOGY 60 (2011) 975 982 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Kidney Cancer Editorial by Eric C. Umbreit and R. Houston Thompson on pp.
More informationLong-term Survival in Patients Undergoing Radical Nephrectomy and Inferior Vena Cava Thrombectomy: Single-Center Experience
EUROPEAN UROLOGY 57 (2010) 667 672 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Long-term Survival in Patients Undergoing Radical Nephrectomy and Inferior
More informationSurgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer
More informationEUROPEAN UROLOGY 57 (2010)
EUROPEAN UROLOGY 57 (2010) 661 666 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Hybrid Renal Cell Carcinomas Containing Histopathologic Features of Chromophobe
More informationThe Changing Evolution of Renal Tumours: A Single Center Experience over atwo-decade Period
European Urology European Urology 45 (2004) 490 494 The Changing Evolution of Renal Tumours: A Single Center Experience over atwo-decade Period Jean-Jacques Patard a,*, Hicham Tazi a, Karim Bensalah a,
More informationRadical Nephrectomy for Renal Cell Carcinoma Its Contemporary Role Related to Histologic Type, Tumor Size, and Nodal Status: A Retrospective Study
AJCP /ORIGINAL ARTICLE Radical Nephrectomy for Renal Cell Carcinoma Its Contemporary Role Related to Histologic Type, Tumor Size, and Nodal Status: A Retrospective Study Kamran M. Mirza, MD, PhD, Jerome
More informationResearch Article Multifocal Renal Cell Carcinoma: Clinicopathologic Features and Outcomes for Tumors 4cm
Hindawi Publishing Corporation Advances in Urology Volume 28, Article ID 51891, 7 pages doi:1.1155/28/51891 Research Article Renal Cell Carcinoma: Clinicopathologic Features and Outcomes for Tumors 4cm
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationWHAT IS THE ROLE OF ACTIVE SURVEILLANCE
WHAT IS THE ROLE OF ACTIVE SURVEILLANCE IN THE CONTEXT OF RENAL ABLATION AND PARTIAL NEPHRECTOMY? Alessandro Volpe University of Eastern Piedmont Novara, Italy RCC INCIDENCE SEER DATABASE (1975-2006) RCC
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationEvaluation of pt2 subdivisions in the TNM staging system for prostate cancer
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology HONG et al. BJUI BJU INTERNATIONAL Evaluation of pt2 subdivisions in the TNM staging system for prostate cancer Sung Kyu Hong, Byung Kyu
More informationClinical Stage Migration and Survival for Renal Cell Carcinoma in the United States
ava ilable at www.sciencedirect.com journa l homepage: euoncology.europeanurology.com Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States Hiten D. Patel *, Mohit Gupta,
More informationPrognostic Impact of the 2009 UICC/AJCC TNM Staging System for Renal Cell Carcinoma with Venous Extension
EUROPEAN UROLOGY 59 (2011) 120 127 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Prognostic Impact of the 2009 UICC/AJCC TNM Staging System for Renal Cell Carcinoma
More informationNumber of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival
Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,
More informationThe pt1a and pt1b category subdivision in renal cell carcinoma: is it reflected by differences in tumour biology?
Original Article pt1a AND pt1b RCC LANGNER et al. The pt1a and pt1b category subdivision in renal cell carcinoma: is it reflected by differences in tumour biology? CORD LANGNER, MANFRED RATSCHEK, PETER
More informationHistologic Tumor Necrosis Is an Independent Prognostic Indicator for Clear Cell and Papillary Renal Cell Carcinoma
Anatomic Pathology / Tumor Necrosis in Renal Cell Carcinoma Histologic Tumor Necrosis Is an Independent Prognostic Indicator for Clear Cell and Papillary Renal Cell Carcinoma Martin Pichler, MD, 1 * Georg
More informationImpact of Venous Tumour Thrombus Consistency (Solid vs Friable) on Cancer-specific Survival in Patients with Renal Cell Carcinoma
EUROPEAN UROLOGY 60 (2011) 358 365 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Impact of Venous Tumour Thrombus Consistency (Solid vs Friable) on Cancer-specific
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationXiang Hu*, Liang Cao*, Yi Yu. Introduction
Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang
More informationClinical Symptoms Predict Poor Overall Survival in Chronic-dialysis Patients with Renal Cell Carcinoma Associated with End-stage Renal Disease
Jpn J Clin Oncol 2014;44(11)1096 1100 doi:10.1093/jjco/hyu117 Advance Access Publication 19 August 2014 Clinical Symptoms Predict Poor Overall Survival in Chronic-dialysis Patients with Renal Cell Carcinoma
More informationREAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO
REAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO Alain Ravaud, MD.PhD Bordeaux. France DISCLOSURES Consultant for: Pfizer, Novartis, GlaxoSmithKline, Roche, Bristol-Myers Squibb Institutional
More informationProspective multi-center study of oncologic outcomes of robot-assisted partial nephrectomy for pt1 renal cell carcinoma
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2012 Prospective multi-center study of oncologic outcomes of robot-assisted partial nephrectomy for pt1 renal cell
More informationWe are IntechOpen, the first native scientific publisher of Open Access books. International authors and editors. Our authors are among the TOP 1%
We are IntechOpen, the first native scientific publisher of Open Access books 3,350 108,000 1.7 M Open access books available International authors and editors Downloads Our authors are among the 151 Countries
More informationRadiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience
Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience Poster No.: RO-0003 Congress: RANZCR FRO 2012 Type: Scientific Exhibit Authors: C. Harrington,
More informationThe Karakiewicz Nomogram Is the Most Useful Clinical Predictor for Survival Outcomes in Patients With Localized Renal Cell Carcinoma
The Karakiewicz Nomogram Is the Most Useful Clinical Predictor for Survival Outcomes in Patients With Localized Renal Cell Carcinoma Min-Han Tan, MBBS, MRCP 1,2,3 ; Huihua Li, PhD 4 ; Caroline Victoria
More informationCanadian Urological Association guidelines for followup of patients after treatment of nonmetastatic
Canadian Urological Association guidelines for followup of patients after treatment of nonmetastatic renal cell carcinoma Wassim Kassouf, Leonardo L. Monteiro, Darrel E. Drachenberg, Adrian S. Fairey,
More informationCharacterization of Patients with Poor-
Characterization of Patients with Poor- Risk Metastatic Renal Cell Carcinoma Hamieh L 1 *, McKay RR 1 *, Lin X 2, Simantov R 2, Choueiri TK 1 *Equal contributions 1 Dana-Farber Cancer Institute, Boston,
More informationPatient Reported Weight Loss Predicts Recurrence Rate in Renal Cell Cancer Cases after Nephrectomy
DOI:10.22034/APJCP.2018.19.4.891 RESEARCH ARTICLE Editorial Process: Submission:01/04/2017 Acceptance:09/11/2017 Patient Reported Weight Loss Predicts Recurrence Rate in Renal Cell Cancer Cases after Nephrectomy
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationReflections on the current knowledge of epidemiology, treatment and prognosis for renal cell carcinoma Hew, M.N.
UvA-DARE (Digital Academic Repository) Reflections on the current knowledge of epidemiology, treatment and prognosis for renal cell carcinoma Hew, M.N. Link to publication Citation for published version
More informationEUROPEAN UROLOGY 58 (2010)
EUROPEAN UROLOGY 58 (2010) 551 558 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Prostate Cancer Prevention Trial and European Randomized Study of Screening
More informationTransitional Cell Carcinoma of the Ureter: Prognostic Factors Influencing Progression and Survival
european urology 51 (2007) 1281 1288 available at www.sciencedirect.com journal homepage: www.europeanurology.com Urothelial Cancer Transitional Cell Carcinoma of the Ureter: Prognostic Factors Influencing
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationComparison of Glomerular Filtration Rate (GFR) (RCC)
Merit Research Journal of Medicine and Medical Sciences (ISSN: 2354-323X) Vol. 3(10) pp. 467-471, October, 2015 Available online http://www.meritresearchjournals.org/mms/index.htm Copyright 2015 Merit
More informationCarcinoma renale (I): Posters Review. Elena Verzoni Oncologia Medica 1 SS.Oncologia Genitourinaria Fondazione IRCCS Istituto Nazionale Tumori Milano
Carcinoma renale (I): Posters Review Elena Verzoni Oncologia Medica 1 SS.Oncologia Genitourinaria Fondazione IRCCS Istituto Nazionale Tumori Milano Agenda: Best Posters in Localized RCC Surgery: CN (#
More informationPatient Selection for Surgery in RCC with Thrombus. E. Jason Abel, M.D.
Patient Selection for Surgery in RCC with Thrombus E. Jason Abel, M.D. RCC with venous invasion Venous invasion occurs in ~10% of RCC Surgery more complex Increased risk for morbidity Thrombus may be confined
More informationAJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center
AJCC Cancer Staging 8 th Edition Prostate Chapter 58 Judd W Moul, MD, FACS Executive Committee, AJCC Professor and Director, Duke Prostate Center Duke University Durham, North Carolina Validating science.
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationeuropean urology 55 (2009)
european urology 55 (2009) 261 270 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by George N. Thalmann on pp. 271 272 of this
More informationNatural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry
2015;112:872 876 Natural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry PETER L. JERNIGAN, MD, KOFFI WIMA, MS, DENNIS J. HANSEMAN, PhD, RICHARD
More informationEUROPEAN UROLOGY 62 (2012)
EUROPEAN UROLOGY 62 (2012) 745 752 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Allison S. Glass, Matthew R. Cooperberg and
More informationWHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?
CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19
More informationRadical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients
Original Article : oncologic outcome in 271 Chinese patients Zhi-Ling Zhang, Pei Dong, Yong-Hong Li, Zhuo-Wei Liu, Kai Yao, Hui Han, Zi-Ke Qin and Fang-Jian Zhou Abstract Few large scale studies have reported
More informationThe Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
More informationRAPN. in T1b Renal Masses? A. Mottrie. G. Denaeyer, P. Schatteman, G. Novara
RAPN in T1b Renal Masses? A. Mottrie G. Denaeyer, P. Schatteman, G. Novara Department of Urology O.L.V. Clinic Aalst OLV Vattikuti Robotic Surgery Institute Aalst Belgium Guidelines on Renal Cell Carcinoma
More informationAnalysis of the outcome of young age tongue squamous cell carcinoma
Jeon et al. Maxillofacial Plastic and Reconstructive Surgery (2017) 39:41 DOI 10.1186/s40902-017-0139-8 Maxillofacial Plastic and Reconstructive Surgery RESEARCH Open Access Analysis of the outcome of
More informationIndications For Partial
Indications For Partial Nephrectomy Christopher G. Wood, M. D., FACS Professor and Deputy Chairman Douglas E. Johnson, M. D. Endowed Professorship in Urology Department of Urology The University of Texas
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationRelating Prognosis in Chromophobe Renal Cell Carcinoma to the Chromophobe Tumor Grading System
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.4.239 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.4.239&domain=pdf&date_stamp=2014-04-17
More informationSurgeons Perspective: LN as a Draining Pattern. Jose A. Karam, MD, FACS Associate Professor Department of Urology
Surgeons Perspective: LN as a Draining Pattern Jose A. Karam, MD, FACS Associate Professor Department of Urology Disclosures EMD Serono, Pfizer, Novartis: Advisory board/consultant Disclosures I perform
More informationSurgical outcomes of nephrectomy for elderly patients with renal cell carcinoma
Original Article Surgical outcomes of nephrectomy for elderly patients with renal cell carcinoma Xiaomin Gao 1, Liang Hu 2, Yue Pan 3, Lei Zheng 4 ABSTRACT Objective: The feasibility of curative surgery
More informationPrognostic evaluation of clear cell renal cell carcinoma
ORIGINAL ARTICLE Architectural Patterns are a Relevant Morphologic Grading System for Clear Cell Renal Cell Carcinoma Prognosis Assessment Comparisons With WHO/ISUP Grade and Integrated Staging Systems
More informationDisease-specific death and metastasis do not occur in patients with Gleason score 6 at radical prostatectomy
Disease-specific death and metastasis do not occur in patients with at radical prostatectomy Charlotte F. Kweldam, Mark F. Wildhagen*, Chris H. Bangma* and Geert J.L.H. van Leenders Departments of Pathology,
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationORIGINAL ARTICLE. World J Urol (2011) 29: DOI /s
World J Urol (2011) 29:487 494 DOI 10.1007/s00345-011-0645-8 ORIGINAL ARTICLE Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial
More informationOriginal Article Clinicopathologic Features of Renal Cell Carcinoma in Young Adults: A Comparison Study with Renal Cell Carcinoma in Older Patients
Int J Clin Exp Pathol (29) 2, 489-493 www.ijcep.com/ijcep8122 Original Article Clinicopathologic Features of Renal Cell Carcinoma in Young Adults: A Comparison Study with Renal Cell Carcinoma in Older
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationRENAL CANCER GUIDELINES
Greater Manchester and Cheshire Cancer Network RENAL CANCER GUIDELINES Agreed by Urology CSG: July 2010 Review Date: July 2012 Renal Cancer Guidelines 1. Introduction 1.1 Kidney cancer accounts for 3%
More informationImpact of lymphadenectomy in management of renal cell carcinoma
Journal of the Egyptian National Cancer Institute (2012) 24, 57 61 Cairo University Journal of the Egyptian National Cancer Institute www.nci.cu.adu.eg www.sciencedirect.com ORIGINAL ARTICLE Impact of
More informationCanadian Guidelines for Management of the Small Renal Mass (SRM)
Canadian Guidelines for Management of the Small Renal Mass (SRM) Michael A.S. Jewett*, Ricardo Rendon, Louis Lacombe, Pierre I. Karakiewicz, Simon Tanguay, Wes Kassouf, Mike Leveridge, Ilias Cagiannos,
More informationVincenzo Ficarra. Direttore Clinica di Urologia Azienda Ospedaliera Universitaria di Udine
Best Papers on Kidney Cancer Vincenzo Ficarra Direttore Clinica di Urologia Azienda Ospedaliera Universitaria di Udine Uro-oncological oncological topics Renal Tumor biopsy Positive Surgical Margins after
More informationPrognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will Be Used?
european urology supplements 8 (2009) 478 482 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will
More informationImpact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery
Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation
More informationAre Prostate Carcinoma Clinical Stages T1c and T2 Similar?
Clinical Urology Are Clinical Stages T1c and T2 Similar? International Braz J Urol Vol. 32 (2): 165-171, March - April, 2006 Are Prostate Carcinoma Clinical Stages T1c and T2 Similar? Athanase Billis,
More informationComparison of radiographic and pathologic sizes of renal tumors
ORIGINAL Article Vol. 39 (2): 189-194, March - April, 2013 doi: 10.1590/S1677-5538.IBJU.2013.02.06 Comparison of radiographic and pathologic sizes of renal tumors Wei Chen, Linhui Wang, Qing Yang, Bing
More information